The company is committed to advancing wellness and is the largest producer of World Health Organization (WHO) pre-qualified HIV/AIDS and Malaria treatments in the region.

[3] Qcil currently produces TLD (a combination of tenofovir, lamivudine and dolutegravir), the latest first-line treatment used to treat and prevent HIV/AIDS.

Qcil also manufactures antimalarials (ACTs), including Lumartem, containing artemisinin and lumefantrine,[4] and the Hepatitis B generic medicines Texavir and Zentair.

Qcil's pharmaceutical manufacturing plant is located in Luzira, an industrial area in Nakawa Division in south-eastern Kampala.

In November 2023, Africa Capitalworks (ACW) acquired Cipla's 51.18% interest in the issued ordinary shares of the company.

[11] As of October 2024, as reported by the Daily Monitor, QCIL was contemplating building a new US$50 million production line to manufacture anti-TB and anti-cancer medication.